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135 Intravenous antibiotic treatment in children with cystic ﬁbrosis:
home versus hospital setting
M. Proesmans1, L. Heyns2, P. Moons2, T. Havermans1, K. De Boeck1. 1Pediatric
Pulmonology, University Hospital, Leuven, Belgium; 2Centre for Nursing Research,
Catholic University, Leuven, Belgium
Several studies compared the efﬁcacy and safety of home versus hospital intravenous
antibiotic (ivAB) therapy in cystic ﬁbrosis (CF) patients. Few concern paediatric
data.
The aim of our study is to compare the outcome of ivAB for pulmonary infection
in CF children in the home or hospital setting.
This retrospective study with single centre data from 1999 to 2004 in CF patients
(age >5 and <20 years). Choice of treatment location was based on patient’s
preference, social background, estimation of competence and adherence. The 1st
treatment per year was analysed for patients with an experience of at least 4 ivAB
treatments. Primary outcome parameters: change in weight and FEV1. Secondary
outcome parameters: change in IgG and complications.
Results: 167 treatment observations (TO) were analysed in 54 patients. Mean age
was 14.4 years with a mean BMI z-score of −1.3 and an mean FEV1% of 62%.
124 TO’s concerned patients with chronic P aeruginosa infection. 74 TO’s were
home and 93 were hospital treatments. The 2 settings only differed signiﬁcantly at
baseline with regard to gender (56/74 female in home vs 38/93 in hospital) and
higher IgG in home group.
Lung function improvement (FEV1% + 8% in home and + 7% in hosp) and weight
gain (+0.7 kg and + 0.5 kg) were comparable in the 2 settings. Total IgG decreased
more in the hospital setting (−66mg% versus −18mg% respectively), however
this was not statistically different. Complications were rare in each group (allergic
reaction to AB: 2 in each group; hemoptoe: 2 in hosp; pneumothorax: 1 in home
group).
Conclusion: The outcome of ivAB therapy for lung infection in children and
adolescents with CF was comparable in the home and hospital setting.
136 The degree of change in FEV1 and FVC after 2 weeks of
intravenous antibiotics for severe pulmonary exacerbation in
adult patients with cystic ﬁbrosis
N.A. Jarad, C. Stanley, W. Gunasekera. Adult Cystic Fibrosis Centre, Bristol Royal
Inﬁrmary, Bristol, United Kingdom
Background: In order to design adequately powered interventional clinical trials
during pulmonary exacerbations (P Exs) expected changes in FEV1 and FVC after
an intravenous (IV) course of antibiotics alone are required. There has been no
published information on this.
Patients and methods: A total 106 P Exs in 47 adult CF patients (23 females) who
underwent IV antibiotics due to severe P Exs were investigated. Their mean age
was 26 years (range 18−38). Their mean (SD) baseline FEV1 was 45% (24.4%)
and baseline FVC 60.0% (24.2%). All measurements were performed using a daily
calibrated same lung function devices by the same group of physiologists. Changes
in FEV1 were calculated after 2 week course of IV antibiotics.
Results: Baseline FEV1 correlated with baseline FVC (r = 0.81, P< 0.0001). There
were wide variation in changes of FEV1 and FVC. Using paired t-test mean change
in FEV1 was 120ml, (SD 260ml), P< 0.0001 and mean change in FVC was 155ml,
SD 380ml, P< 0.0001.
There was no difference in change in either FEV1 or FVC between male and female
patients. Change in FEV1 did not correlate with baseline of FEV1, whereas there
was a weak inverse correlation between change in FVC and baseline FVC, r = −0.33,
P = 0.007. Change in FEV1 correlated with change in FVC r = 0.70, P< 0.0001.
Conclusions: After 2 week course of IV antibiotics there was an average improve-
ment of 120ml and 155ml in FEV1 and FVC respectively. There was a wide
variation in response to IV antibiotics including reduction in FEV1 and FVC after
some courses of IV antibiotics. These changes need too be born in mind when
designing clinical trials for intervention in CF pulmonary exacerbations
137 Concordance between intravenous antibiotics (IV)and in vitro
susceptibility of sputum bacteria does not inﬂuence the outcome
of pulmonary exacerbations in adult cystic ﬁbrosis patients
N.A. Jarad, C. Stanley, W. Gunasekera, S. Webster. Adult Cystic Fibrosis Centre,
Bristol Royal Inﬁrmary, Bristol, United Kingdom
Background: This study investigates the outcome of severe P Ex according to
concordance between IV antibiotics given and the in vitro sensitivity of the bacteria
isolated at the start of the treatment.
Patients and methods: A total of 94 P Exs requiring intravenous (IV) antibiotics
in 54 adult patients (19 female) were investigated. The mean age of patients was
27.4 (range 18−38) years. Antibiotics were started according to the sensitivity
identiﬁed at the most recent sputum samples prior to P Ex or according to the best
combinations previously used successfully in that patient. Concordance between
the sensitivity pattern found at the exacerbation sputum sample and the antibiotics
given was divided into 3 bands: band 1: concordance 0−24% (19 P Exs), band 2:
25−74% (29 P Exs), band 3: 75–100% (46 P Exs). Outcome measures were: changes
in FEV1 and FVC for the P Ex.
Results: There was no difference in baseline FEV1, and FVC amongst the three
bands of concordance. Changes in FEV1 or in FVC at the end of P Ex did not differ
in the three bands of concordance. Mean (SD) changes in FEV1 were 220 (218)ml
for band 1, 91 (230)ml for band 2 and 117 (303)ml for band 3. Mean (SD) changes
for FVC for the three bands respectively were 207 (318)ml for band 1, 182 (436)ml
for band 2 and 106 (385) for band 3; P NS for both analyses.
Conclusions: Concordance of IV antibiotic and the results of sputum sensitivity
did not inﬂuence the outcome of P Ex. This study and others calls for better
methods of identifying the sensitivity proﬁle of sputum bacteria to guide the choice
of antibiotics during P Ex.
138 Effects of antibiotic treatment of initial Pseudomonas aeruginosa
colonization on acquisition of chronic infection in cystic ﬁbrosis
S. Fustik1, T. Jakovska1, L. Spirevska1, V. Kotevska2. 1Pediatric Clinic, Clinical
Centre, Skopje, Macedonia; 2Institute for Microbiology, Skopje, Macedonia
The majority of patients with cystic ﬁbrosis (CF) acquire chronic Pseudomonas
aeruginosa (PA) lung infection after a period of intermittent infection. The negative
impact of chronic PA infection on prognosis in CF is well established.
In 2000, we introduced an eradication regime at time of initial or intermittent PA
isolation consisting of inhaled colistin or gentamycin and oral ciproﬂoxacin for
6 weeks. If unsuccessful, a course of intravenous anti-PA antibiotics for 2 weeks
was advised. Before 2000, no speciﬁc therapy was initiated at ﬁrst PA positivity.
The aim of the study was to evaluate the impact of this therapeutic approach on
the rate of acquisition of chronic PA infection in CF patients. Chronic PA infection
was deﬁned as persistent presence of PA in sputum samples at least 6 consecutive
months and/or presence of two or more PA precipitants. Intermittent PA colonization
was deﬁned as a culture of PA at least once and presence of normal levels of
precipitating antibodies against PA (0−1). During the study period from 2000 to
2006, eradication therapy was performed in 39 (range 1−5) CF patients. Six of the
treated patients (15.6%) developed chronic PA infection. Chronic PA infection was
already established in 3 patents when they ﬁrst attended the clinic and in 2 patients
who were lost at follow-up for longer period. The rate of acquisition of chronic PA
infection in the study period was 13.7%. In contrast, in the period from 1994 to
2000, only 4 out of 21 intermittently colonized CF patients remained free of PA. The
early eradication therapy can effectively delay acquisition of chronic PA infection
in considerably proportion of patients with CF and decrease disease progression.
